Cost of illness in benign prostatic hyperplasia: A review

Kovács, Ágnes (2015) Cost of illness in benign prostatic hyperplasia: A review. Society and Economy, 37 (4). pp. 531-542. DOI 10.1556/204.2015.37.4.7

PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader


The paper provides a systematic review on the cost-of-illness studies in an age-associated condition with high prevalence, benign prostatic hyperplasia (BPH), published in Medline between 2005 and 2015. Overall 11 studies were included, which were conducted in 8 countries. In the US, the annual direct medical costs per patient ranged from $255 to $5,729, while in Europe from €253 to €1,251. In 2008, in the UK total annual direct medical costs of BPH were £180.8 million at national level. In the US, overall costs of BPH management in the private sector were estimated at $3.9 billion annually, of which $500 million was attributable to productivity loss (year 1999). Due to demographic factors and possible surgical innovations in the field of urology, the costs of BPH are likely to increase in the future. Over the next decade the age of retirement is projected to rise, consequently, the indirect costs related to aging-associated conditions such as BPH are expected to soar. To promote the transparent and cost-effective management of BPH, development of rational clinical guidelines would be essential that may lead to significant improvement in quality of care as well as reduction in healthcare expenditure.

Item Type:Article
Uncontrolled Keywords:aging healthcare costs, cost-of-illness, benign prostatic hyperplasia
JEL classification:I19 - Health: Other
Divisions:Faculty of Economics > Department of Health Economics
Subjects:Social welfare, insurance, health care
ID Code:2226
Deposited By: Ádám Hoffmann
Deposited On:18 Feb 2016 09:37
Last Modified:13 Dec 2021 09:14

Repository Staff Only: item control page


Downloads per month over past year

View more statistics